Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

NeuroDerm

Biotech & Life Sciences · Rehovot, Israel · Founded 2003 · IPO 2014 Unicorn

Clinical-stage pharmaceutical company developing treatments for central nervous system disorders

Valuation
$1.10B
Market cap · 2026

Investors

2 investors on NeuroDerm's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Robert Taub
Series B+ 1 investor entered at this stage
The Elias Group

Global footprint

Where NeuroDerm has talent and traffic

Workforce by country
7 countries with
team presence
🇮🇱 Israel91.4%
🇺🇸 United States4.5%
🇫🇷 France1.4%
🇵🇹 Portugal0.8%
🇺🇦 Ukraine0.8%
Top 5 of 7 shown
Web traffic by country
700 monthly visits
across markets
🇬🇧 United Kingdom85.7%
🇮🇳 India14.3%
🇮🇱 Israel0%
Top 3 markets shown

Patent intelligence

$46M patent portfolio · 28 active families

Estimated portfolio value
$46M
4.2% of market cap · 2.3× smaller than top peer COMPASS Pathways ($106M)
28 active patent families
Where NeuroDerm innovates CarbidopaDOPA Decarboxylase InhibitorsPharmaceutical drugDepressantDopamine

Where NeuroDerm concentrates vs peers

Each axis is a top-10 topic across NeuroDerm and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about NeuroDerm

An AI-synthesized read of the highest-engagement posts about NeuroDerm on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuroDerm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.